Compare TRVG & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVG | OABI |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | Germany | United States |
| Employees | N/A | 114 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.2M | 253.4M |
| IPO Year | 2015 | N/A |
| Metric | TRVG | OABI |
|---|---|---|
| Price | $2.78 | $1.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $4.09 | ★ $6.67 |
| AVG Volume (30 Days) | 31.6K | ★ 258.6K |
| Earning Date | 04-28-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.59 | $52.42 |
| Revenue Next Year | $8.42 | $64.69 |
| P/E Ratio | $16.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.71 | $1.22 |
| 52 Week High | $5.83 | $2.57 |
| Indicator | TRVG | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 33.58 | 45.49 |
| Support Level | N/A | $1.71 |
| Resistance Level | $3.26 | $1.89 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 0.00 | 21.62 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.